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Abstract T cell tolerance to self-antigens is believed to be
achieved in a two-step process. The first step, called central
tolerance, takes place in the thymus. The second step takes
place outside the thymus in secondary lymphoid organs.
One may ask why two mechanisms are needed to insure
T cell tolerance. These two mechanisms share redundant
functions and dysfunctions, leading to T cell-mediated
autoimmune syndromes. By reviewing the literature on
relevant animal models for T cell tolerance and our own
recent findings, we are providing evidences that only
central tolerance is acting for the skin.
Keywords Central tolerance . Peripheral tolerance .
Skin . Tcells
Introduction
An immune system is built so as to avoid mounting
reactions against normal healthy cells, constituting the
“self”. Immune cells are educated not to recognise self-
antigens. This education is based on the removal of cells
that are too strongly recognising self-antigens from the
active repertoire. Only cells with a low affinity for self-
antigens are spared. These latter cells are expected to be of
the strongest affinity for foreign antigens presented in the
context of a self-major histocompatibility complex.
For T cells, education is mediated in two anatomically
separated steps. A first step, called central tolerance, occurs
in the thymus. There, self-antigens expressed by medullary
thymic epithelial cells (mTEC) are presented directly to
maturating T cells. These antigens can also be presented at
the surface of thymic-resident dendritic cells (DC) via a
cross-presentation process [1]. A strong interaction between
a TCR expressed by developing thymocytes and self-
antigens leads to thymocyte cell death, development arrest
and/or lineage diversion [2], eliminating these cells from
the mature T cell repertoire. Obviously, this mechanism is
efficient for epithelial antigens and tissue-restricted antigens
(TRA) not expressed in mTEC have to be presented in the
thymus to insure a more complete T cell tolerance to self.
This can be performed in two ways. First, the very same
mTEC have the unique property to express TRA, in a so-
called promiscuous fashion, due to the expression of the
specific transcription factor autoimmune regulator [3, 4].
Second, peripheral DC immigrating in the thymus can also
cross-present TRA to maturating thymocytes [5]. Again,
these two pathways of TRA presentation in the thymus lead
to the deletion of the most avid T cells. A second step of T
cell tolerance occurs on mature T cells in secondary
lymphoid organs. It is called peripheral tolerance [6].
There, TRA are picked up by DC in tissues and cross-
presented to naïve mature T cells in lymph nodes draining
the corresponding tissue [7]. This can be done directly by
the migrating DC or perhaps via a transfer of the antigen to
a lymph-node-resident DC [8]. TRA recognition in periph-
eral lymph nodes conducts to T cell tolerance in the steady
state. Here, tolerance is achieved either by cell deletion or
by induction of an unresponsiveness state, called anergy
[9], depending on the self-antigen doses [10]. At that stage,
one may ask why two mechanisms are needed to insure T
cell tolerance. Central and peripheral tolerance may appear
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redundant, rather than being complementary. The absence
of total complementarity between the two mechanisms is
evidenced by the fact that T cell tolerance is not complete,
sparing a repertoire of self-reactive cells harming the host
when appropriately activated in the periphery. This is the
case for patients suffering from insulin-dependent diabetes
mellitus [11], rheumatoid arthritis [12] or multiple sclerosis
[13, 14]. In these autoimmune pathologies, self-reactive T
cells have been shown to attack their target organs,
mediating loss of tissue integrity and function, thereby
conducting to syndrome. In addition, these two tolerance
pathways share redundant dysfunctions. They harbor the
same leakiness in early life [15, 16].
In this study, we will focus on T cell tolerance to skin
antigens. As for most if not all organs, T cell tolerance to
skin is only partial because T cell-mediated autoimmune
manifestations are clinically seen. However, it is not known
at what level(s) the tolerance is failing. We have reviewed
the current knowledge in T cell tolerance to skin antigens
and attempted drawing conclusions for this organ.
Tolerance to keratinocyte antigens
The skin is composed of keratinocytes, target for self-
reactive T cells in the autoimmune bullous pemphigoid
[17]. In healthy individuals, tolerance mechanism(s) must
act on T cells to avoid keratinocyte damages. Recently,
transgenic mouse models based on the expression of a
model antigen specifically in keratinocytes have shed some
light on the pathway used to insure tolerance to keratino-
cyte antigens.
Three different groups have created a mouse expressing
ovalbumin specifically in keratinocytes. This has been done
by using regulatory elements from the keratin 14 (K14) [18,
19] or keratin 5 (K5) promoter [20]. Remarkably, these
investigators observed unanimously that peripheral encoun-
ter of the self-antigen induced cytotoxic effector T cells. To
our knowledge, this constitutes the first example of an
efficient T cell priming upon recognition of a self-antigen in
the periphery under steady-state conditions and, when
numbers of specific T cells are kept low, close to
physiological conditions. For self-antigens expressed else-
where, T cell priming does not occur. Deletion is observed
for antigens expressed in hematopoietic cells [21], prostate
[22] and pancreas [23], while anergy or hypo-responsive-
ness is observed for intestine [24], liver [25] and brain [26]
antigens. For eye antigens, a null event may follow
peripheral T cell recognition of the self-antigen [27]. In
the transgenic models investigated, T cells primed by
keratinocyte antigens are pathogenic, causing damages to
skin resembling graft vs host disease [18, 28] and/or toxic
epidermal necrolysis [20]. Mechanistic studies have been
performed in this model. Antigen-presenting cells involved
in peripheral self-antigen presentation were dependent on
the promoter used. It was found that radio-resistant
Langerhans cells (LC) in the case of the K14 promoter
[29] and radio-sensitive bone-marrow-derived DC in the
case of the K5 promoter [20] were involved. In both cases,
cross-presentation of the self-antigens picked up from
keratinocytes were probed in skin-draining lymph nodes.
This observation argues against the dogma that tissue
dendritic cells migrating to draining lymph nodes in the
steady state mediate T cell tolerance [30], at least for skin
antigens. In the case of keratinocyte antigens, T cell
priming in the periphery has to be counterbalanced to
avoid the so-called horror autoxicus described early by
Ehrlich referring to autoimmune reactions [31]. A regula-
tory pathway suppressing the function of the cytotoxic,
skin-damaging, effector T cells induced has been observed
[32]. This is mediated by a conditioning of LC into a
tolerising state by responding T cells. However, this is
acting too late after induction of cytotoxic T cells to avoid
damage. In fact, central tolerance able to counteract the
peripheral priming for a normal T cell repertoire acts for
keratinocyte antigens [19, 20]. Taken together, these
different models highlight the dominant role of central
tolerance for keratinocyte antigens.
Tolerance to melanocyte antigens
The skin is also composed of melanocytes, which are lining
the basal layer of keratinocytes. Melanocytes are also target
for self-reactive T cells in an autoimmune pathology called
vitiligo [33]. Again, the occurrence of such autoimmune
reactions implies that melanocyte-specific self-reactive T
cells are kept silent in healthy individuals. In an approach
similar to the one described above for keratinocyte
antigens, we have created a model to study T cell tolerance
to tyrosinase, a melanocyte antigen. This was achieved by
the generation of different mouse lines (Tyr-OVA mice)
expressing a model antigen, ovalbumin, specifically in
melanocytes [34]. In these transgenic animals, the model
self-antigen was constantly presented to T cells in periph-
eral lymph nodes. Notably, this presentation neither
involved radio-sensitive bone-marrow-derived cells nor
radio-resistant Langerhans cells. Indeed, self-antigen pre-
sentation also occurred in lymph nodes distant from the
skin, such as mesenteric lymph nodes, known to be devoid
of immigrating skin Langerhans cells [35]. The cells
involved in self-antigen presentation express tyrosinase,
other melanocytic enzymes, such as Trp-1, Trp-2 and
gp100, but are not pigmented. They are therefore likely to
be lymph node-resident melanocyte not fully differentiated
to produce pigment such as those in the skin. Our
60 Semin Immunopathol (2007) 29:59–64
observation is consistent with the fact that melanocytes
resist irradiation (p. 517 of [36]). The presence of
melanocyte in lymph nodes has already been pointed out
in the case of nevi observed in this organ. These nevi,
observed in lymph nodes draining a primary melanoma, are
called nodal nevi [37]. They form compact aggregates of
small cells, similar to cutaneous nevi, and therefore
cytologically distinct from melanoma cells. Proximity of a
primary tumor may induce proliferation of lymph-node-
resident melanocytes. Less frequently, they are formed by
an uncommon pigmented lesion, called blue nevus, devel-
oping in lymph nodes in the absence of cutaneous
melanoma [38]. In this case, they may originate from the
proliferation of melanocytes arrested during their differen-
tiation in lymph nodes [39]. In mice, we observed
melanocytes in skin-draining (inguinal and axillary) and
mesenteric lymph nodes, from 1 to 11 per node section
(Fig. 1). They are located in the sinus and the capsule,
strongly suggesting that they are migrating via the
lymphatic system. In some instances, we observed some
of these cells lining the T cell area. Such a location is
consistent with the site of nodal nevi occurrence. It is
interesting to note that Slingluff et al. [40] has investigated
in detail the mechanisms involved in T cell tolerance to
endogenous tyrosinase. Notably, they also reported that
tyrosinase presentation in skin-draining lymph nodes
involved radio-resistant cells. We observed T cell priming
upon peripheral antigen presentation, while they did not.
This discrepancy may be due to affinity differences with a
priming event for high-affinity T cells. We have used TCR-
transgenic OT-I CD8+ T cells, known to be of high affinity
for their cognate OVA peptide [41]. Slingluff et al. have
used newly generated tyrosinase-specific TCR transgenic
CD8+ T cells, of which affinity has not been reported yet.
The priming we observed was efficient, as it induced fully
differentiated cytotoxic effector CD8+ T cells that persisted
in lymph nodes. These cells did not induce autoimmune
damage to skin melanocytes, as mice did not develop skin
de-pigmentation characteristic for vitiligo. This is likely due
to the absence of skin inflammation in our model. Skin
inflammation has been shown by others to be required to
initiate melanocyte destruction in animals containing a pool
of melanocyte-specific cytotoxic T cells, such as after an
active vaccination protocol against melanocyte antigens
[42]. However, the presence of cytotoxic T cells in
lymphoid organs represents a serious autoimmune threat
that needs to be tightly controlled.
For tyrosinase used in our study, thymic deletion of
specific T cells may represent a safe alternative to avoid T
cell priming in the periphery. Indeed, we observed that 60%
of the OVA-specific T cells are deleted in the thymus of
double transgenic OT-I x Tyr-OVA mice. Thymic cell
deletion was complemented by TCR tuning on an addi-
tional 20% of the cells, and only 20% of OVA-specific cells
were able to escape central tolerance. This escape from
central tolerance is likely due to the exaggerated number of
specific T cells in thymi from double transgenic mice.
Indeed, OVA-specific cells could neither be observed in the
periphery from naïve nor after repeated vaccinations in
single transgenic Tyr-OVA mice. This indicates that central
tolerance was complete for an endogenous T cell repertoire.
In the periphery, the escaping cells encountered the self-
antigen in lymph nodes, became cytotoxic CD8+ T cells and
persisted similarly to adoptively transferred naïve T cells
from mice not expressing the self-antigen (OT-I mice).
How is central tolerance to tyrosinase achieved? As
discussed in the “Introduction”, central tolerance can be
achieved in three distinct ways: direct presentation by
mTEC or cross-presentation by DC either resident in the
thymus or immigrating from the periphery. Our present
observations do not allow us to fully conclude. However,
Slingluff et al. [40] performed thymus exchange between
wild type (WT) and albino mice, deficient in the tyrosinase
gene, to investigate the contribution of this organ in the
establishment of tolerance to tyrosinase. They did not
observe any influence of the thymus on the reactivity to
tyrosinase for peripheral T cells. Thymectomised albino
mice reconstituted with a WT thymus showed the same
degree of peripheral reactivity than fully albino mice. In
addition, grafting of thymi from albino mice to thymec-
tomised WT mice did not allow the recovery of a high-
affinity T cell reactivity in the periphery. It is unlikely that
alternate cervical thymi [43, 44] could, on their own,
replace cervical thymus function in this kind of experiment.
Fig. 1 Lymph-node-resident melanocytes. A skin-draining lymph
node was immunostained with the polyclonal anti-tyrosinase pep7
antiserum [50]. Tyrosinase-expressing melanocytes are marked with
an arrow. The insert is showing a high-power microscopy image of a
stained cell
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To our knowledge, such complementation of thoracic thymi
by cervical thymi has never been reported. Experiments by
Slingluff et al. indicate that tyrosinase expression in the
thymus, despite having been probed in mTEC (our own
observation and in [45]), unexpectedly does not serve any
role in thymocyte education. Hence, central tolerance is
likely to be executed by peripheral DC cross-presenting the
self-antigen to thymocytes (Fig. 2). The central tolerance
we have observed in our Tyr-OVA mice does not depend on
the sub-cellular localisation of the self-antigen in melano-
cytes. It is as efficient for a secreted antigen than for an
antigen expressed at the cell membrane and even for an
antigen sequestrated into the cytosol. So is the priming
observed in the periphery. Therefore, central tolerance may
also be effective for a wide set of melanocyte antigens.
Concluding remarks
Achievement of T cell tolerance cannot be considered as
optimal, as an important human population is suffering from
diverse T cell-mediated autoimmune pathologies. As an
example, vitiligo affects up to 2% of a homogeneous
population [46]. Recent progresses made in animal models
created to investigate T cell tolerance are telling us that T cell
tolerance is a complex multi-step process, dependent on the
organ considered. In this study, we provide compelling
evidence that the skin is a special organ in terms of T cell
tolerance. Indeed, presentation of self-antigens from skin
keratinocytes or melanocytes resulted in the periphery in an
efficient T cell priming. For these self-antigens, central
tolerance is a dominant mechanism.
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Fig. 2 Postulated central path-
way mediating T cell tolerance
to tyrosinase. 1 Melanocytes are
localised at the base of hair
follicles. LC and dermal DC can
pick up antigens from melano-
cytes and migrate to the draining
lymph nodes. 2 Within the
draining lymph nodes, immi-
grating loaded LC, dermal DC
and lymph-node-resident mela-
nocytes have no obvious role in
the induction of peripheral tol-
erance to tyrosinase. 3 Periph-
eral DC loaded with tyrosinase
antigens can migrate in the
thymus and eliminate maturing
T cells presenting a too-high-
affinity TCR for tyrosinase. In
the thymus, mTEC expressing
tyrosinase and resident DC have
no obvious role in the central
tolerance to tyrosinase
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What are these new findings telling us? It is telling us
that vitiligo is likely to originate from a defect in central
tolerance that must be combined to an environmental factor
leading to skin inflammation, owing to the requirement of
the latter factor to start the damaging process. It will be of
interest to evaluate whether central tolerance defect is
similar among all individuals, rendering environmental
factor(s) the only variable, or whether central tolerance
efficacy is variable between individuals. The observations
presented herein are also raising doubts regarding the
existence of peripheral tolerance to skin antigens. TRA
are presented in the periphery in the steady state to survey
for mature T cells newly emigrating from the thymus with
potential self-reactivity due to central tolerance escape. In
this steady-state condition, there is no infection, conse-
quently no danger signal and no strong co-stimulatory
activity of DC [47]. Hence, steady-state presentation should
induce T cell tolerance. However, any event leading to DC
activation in the periphery during TRA presentation may
change a tolerising event into a priming event, leading to
the generation of effector self-reactive T cells able to
damage tissues. Autoimmune reactions induced by by-
stander DC activation have been demonstrated in several
animal models [48], and we know that we are too much
exposed to pathogens to believe that such bystander events
are rare. Taken together, this leads to the idea that
mechanisms acting for peripheral tolerance are not mediat-
ed without any risk for the host. In contrast, central
tolerance by presentation of self-antigens to thymocytes
appears less risky. There bystander activation of DC, either
thymic resident or immigrating from the periphery, should
even lead to an increased central tolerance based on the
requirement of co-stimulatory signals for this process [49].
Based on all these considerations, the skin, exposed to
many infections and therefore containing bystander-activat-
ed DC, may have evolved in a way to suppress peripheral
tolerance pathways compared to other organs less exposed
to infection.
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